 Eli Lilly  Co said its fourthquarter profit declined  as the drug maker entered a new round of patent expirations that will erode sales of top drugs throughout  The Indianapolis company lost US patent protection for its No  product the antidepressant Cymbalta in December which triggered the introduction of competing lowcost generic copies Lilly is due to lose patent protection for bonebuilding drug Evista in March which will further contribute to sales and profit declines for 